MoneyWorks4Me

Aurobindo Pharma gets nod to raise $350 million via QIP

23 Jan 2015 Evaluate

Aurobindo Pharma has received its board approval to raise up to an amount of $350 million through issue shares to Qualified Institutional Buyers. The approval to issue shares under Qualified Institutional Placement (QIP) was secured at a meeting held on January 21, 2015.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1628.75 -2.25 (-0.14%)
28-Aug-2026 12:57 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1918.55
Dr. Reddys Labs. 1182.55
Cipla 1414.00
Lupin 2167.00
Zydus Lifesciences 1178.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: